Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zai Lab's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zai Lab's regulatory disclosures and financial reporting.
Zai Lab Limited (ZLAB) Q2 2025 10-Q highlights: Net product revenue rose 9 % YoY to $109.1 million, lifting total revenue to $110.0 million. Cost controls drove a 28 % YoY cut in operating loss to $54.9 million and shrank net loss by 49 % to $40.7 million (-$0.04/share). Six-month revenue climbed 15 % to $216.5 million, with net loss down 33 % to $89.2 million.
Growth came from VYVGART (+14 %), NUZYRA (+16 %), XACDURO and AUGTYRO launches, partly offset by a 9 % decline in ZEJULA. R&D expense fell 18 % YoY, SG&A fell 11 %, and operating cash outflow improved to -$92.7 million from -$132.3 million. Cash & equivalents surged to $732.2 million after maturing $330 million of short-term investments; short-term debt increased to $174.5 million (2.66 % avg. rate).
- Q2 gross margin ~61 % (product revenue vs. cost of product revenue).
- Shares outstanding: 1.10 billion; ADS float 421.7 million.
- Pivotal pipeline events: Fast Track for ZL-1310 (SCLC), positive Phase III data for bemarituzumab (FGFR2b gastric), PANOVA-3 success for TTFields, NMPA sNDA acceptance for repotrectinib.
- Subsequent event: doubled CMB revolving facility to RMB500 million (~$69.6 million) on 6 Aug 2025.
Despite stronger top-line momentum and disciplined spending, Zai Lab remains loss-making and dependent on capital markets and credit lines while advancing an expansive late-stage pipeline.
Zai Lab Limited (NASDAQ: ZLAB) filed a Form 144 indicating that insider Ying Du plans to sell 7,072 American Depositary Shares (ADS) on 02 July 2025 through Fidelity Brokerage Services. The proposed transaction is valued at US$249,143.73, representing roughly 0.0015 % of the company’s 486.9 million ADS outstanding, and stems from the vesting of restricted stock on 01 July 2025.
The filing also discloses that the same insider has already sold 235,729 ADS between 02 April 2025 and 30 June 2025, generating an estimated US$7.1 million in gross proceeds. These prior sales were executed in eight tranches ranging from 2,945–50,000 ADS each.
Although the absolute dollar value of the individual sale is modest relative to Zai Lab’s market capitalization, the cumulative selling pattern may be interpreted by some investors as a signal of insider profit-taking. No new operational, earnings or strategic information is provided in this filing; the document is strictly a regulatory notice satisfying Rule 144 requirements.
Zai Lab (NASDAQ:ZLAB) filed a Form 4 revealing that Chief Legal Officer Edmondson Frazor Titus III’s 14,600 RSUs vested on 25 Jun 2025, converting into the same number of ADSs.
To cover withholding taxes, he sold 5,877 ADSs on 26 Jun 2025 at $36.132 (≈ $213 k), coded “S”. Post-transaction, his direct stake stands at 44,975 ADSs, each ADS representing ten ordinary shares.
The sale, while automatic under a Rule 10b5-1 plan, equals roughly 12 % of his pre-sale position, crossing the 5 % materiality threshold and offering investors a governance data-point rather than a directional signal.
Key Form 4 details for Zai Lab Ltd (ZLAB): On 25 June 2025, Chairperson & CEO Ying Du received 58,800 American Depositary Shares (ADS) upon the vesting of previously granted Restricted Share Units (RSUs). Each ADS represents ten ordinary shares. The conversion was reported under transaction code “M,” indicating a delivery of shares without cash consideration.
On 26 June 2025 the executive executed an automatic sale (code “S”) of 23,669 ADS at US $36.132 per ADS to satisfy tax-withholding obligations triggered by the vesting event. After both transactions, Du’s direct beneficial ownership stands at 514,982 ADS.
Net effect: the CEO’s holdings increased by 35,131 ADS relative to the amount immediately prior to the RSU vesting, reinforcing management’s equity alignment while acknowledging routine tax-related disposals. No derivative positions remain in connection with this RSU tranche.
The RSUs follow a four-year vesting schedule that began on 25 June 2023; future anniversaries may lead to similar withhold-to-cover sales. Investors typically view net ownership increases as a positive governance signal, although periodic sales could add modest near-term share supply.